Drugs / BIP48
BIP48
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01889849 | Oct 2010 → Aug 2011 | chronic hepatitis C virus infection | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT01623336 | Jan 2012 → Aug 2016 | chronic hepatitis C virus infection | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BIP 48 | “The aim of this study was to compare the pharmacokinetic properties of BIP48 (pegylated interferon alfa-2b from Bio-Manguinhos/Fiocruz, Brazil) to those of PEGASYS®...” PMID 29301580 ↗ Jan 2018 |
| Known as | Peginterferon alfa 2b 48kDA | “BIP 48 (Peginterferon alfa 2b 48kDA)will be administered in a dose of 180 micrograms, once a week, subcutaneous” NCT01623336 ↗ |
| Known as | pegylated interferon alfa-2b | “The aim of this study was to compare the pharmacokinetic properties of BIP48 (pegylated interferon alfa-2b from Bio-Manguinhos/Fiocruz, Brazil) to those of PEGASYS®...” PMID 29301580 ↗ Jan 2018 |
| Modality | Protein / enzyme biologic | “BIP48 (48 kDa peginterferon alfa-2b)” NCT01623336 ↗ |
| Route | Subcutaneous | “180 micrograms, once a week, subcutaneous” NCT01623336 ↗ |